Skanska Secures Major Contract for Biotechnology Facility
Skanska has recently announced a noteworthy contract with the University of Virginia. This contract involves the construction of a cutting-edge facility known as the Paul and Diane Manning Institute of Biotechnology. The total value of this contract stands at an impressive USD 116 million, which translates to approximately SEK 1.2 billion. This agreement is significant and will contribute to Skanska's US order bookings in the upcoming third quarter.
Innovative Facility Design and Purpose
Upon completion, the five-story biotechnology institute will encompass around 33,000 square meters, equating to roughly 354,000 square feet. It is designed to support a unique translational research program, fostering innovation in the life sciences industry.
State-of-the-Art Laboratory Spaces
The new building will feature modular laboratory spaces that can serve various research needs. Comprehensive research facilities will be included, which are essential for academia and industry collaborations. This facility aims to accommodate between 100 to 150 researchers along with partnering biotechnology companies, creating a hub for collaboration in science and technology.
Construction Timeline and Expectations
Construction work commenced in late 2023, with a projection for completion set in the fourth quarter of 2027. This timeline illustrates Skanska's commitment to timely project delivery while ensuring quality and efficiency in the construction process.
Contact Information for Inquiries
For those looking for further information, interested parties can reach out to key representatives:
Ashley Jeffery, Communications Director, USA Building, telephone +1 813 459 3682.
Andreas Joons, Press Officer, Skanska Group, telephone +46 (0)10 449 04 94.
Direct line for media inquiries is +46 (0)10 448 88 99.
Significance in the Biotechnology Sector
The Paul and Diane Manning Institute of Biotechnology will play a crucial role in advancing biotechnology research. By providing a modern environment and state-of-the-art facilities, this institute aims to enhance collaboration between researchers and biotechnology firms, ultimately driving innovation in this vital sector.
Commitment to the Future of Science
Skanska’s sponsorship of this project shows their dedication to investing in the future of science and healthcare. As the biotechnology field continues to grow and evolve, facilities like this one will be critical for nurturing advancements and breakthroughs.
Frequently Asked Questions
What is the purpose of the Paul and Diane Manning Institute of Biotechnology?
The institute aims to foster translational research and support collaboration among researchers and biotechnology companies.
How large is the biotechnology facility?
The facility will cover approximately 33,000 square meters, providing ample space for laboratories and research activities.
When is the expected completion date for the construction?
The construction is anticipated to be completed in the fourth quarter of 2027.
Who can be contacted for more information about the project?
Ashley Jeffery and Andreas Joons are the primary contacts for inquiries regarding the biotechnology facility.
What are the benefits of this new facility?
This facility will enhance research capabilities, support collaboration, and advance the biotech industry through state-of-the-art infrastructure.
